On January 5, 2022 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported a strategic restructuring (Press release, FierceBiotech, JAN 5, 2022, View Source [SID1234598303]). The company will prioritize its late-stage product opportunities, poziotinib and ROLONTIS (eflapegrastim), and will deprioritize development activities of its early-stage clinical development and research programs. The company has made these decisions following a detailed review of its operations, portfolio and growth opportunities, and will focus its resources accordingly.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The decision to restructure the organization is necessary to focus on our advanced clinical programs that will drive our future growth. I would like to express my appreciation to our colleagues who are affected by this decision and are leaving Spectrum. We are grateful for their dedication and their contributions to advancing our mission," said Tom Riga, President and Chief Executive Officer, Spectrum Pharmaceuticals. "The changes we are implementing are expected to result in a reduction in operating expenses and the extension of the company’s cash runway into 2023."

Spectrum intends to implement the following strategic restructuring initiatives to reduce its expenses and extend its existing cash runway:

Spectrum is prioritizing the development activities for its late-stage assets, poziotinib and ROLONTIS, and will deprioritize work on its early-stage pipeline, FIT Program (IGN 002) and IL-12.
The company restructuring will result in a workforce reduction of approximately 30%.
Operating cash burn is expected to be reduced by 20-25%, which should extend the cash runway into 2023.
The physical footprint of selected facilities will be significantly reduced in 2022.